IPR
Among the published international applications is WO2022190030A1, “A topical formulation for the treatment of skin diseases.” The invention concerns pharmaceutical compositions developed for topical administration and is directed toward therapeutic applications in dermatological conditions. The publication illustrates an emphasis on formulation science, where the selection and combination of active pharmaceutical ingredients and excipients can be engineered to achieve an appropriate dosage form and administration profile.
Another area of innovation is represented by WO2023052977A1, “Compositions, methods and uses thereof,” which reflects research into pharmaceutical compositions and their potential therapeutic applications. The patent portfolio also includes WO2023052974A1, “Ocular compositions and methods for the treatment of ophthalmic diseases and disorders,” highlighting research directed toward ophthalmic therapeutic solutions. These international publications demonstrate the breadth of Avaca Pharma’s intellectual-property activities across different therapeutic and pharmaceutical-development domains.
Avaca Pharma has also developed intellectual property around topical pharmaceutical compositions containing H1 antagonists. The corresponding U.S. patent application was published as US20230020927A1, and the invention subsequently received U.S. Patent No. 11,833,141 in December 2023. The disclosed technology encompasses topical dosage forms such as solutions, sprays, lotions, gels, creams, ointments, and emulsions, with potential applications in the management of allergic skin conditions.
The portfolio further demonstrates an interest in combination-based pharmaceutical strategies. Public patent records identify research involving combinations of therapeutic agents and pharmaceutical compositions intended to address specific disease mechanisms or clinical requirements. Such approaches are important in modern formulation and drug-development research because rational combinations can be investigated for complementary pharmacological activity, improved therapeutic utility, or enhanced patient-management strategies.
Avaca Pharma’s published intellectual property therefore represents more than a collection of individual patent applications; it reflects a broader commitment to pharmaceutical innovation, formulation development, drug-delivery technologies, and translational research. International patent publication provides a mechanism for documenting inventions and establishing a public record of the underlying technological concepts while supporting potential development and commercialization pathways in relevant jurisdictions.
For ZeeVieZee BioPharma, Avaca Pharma’s intellectual-property portfolio represents an important connection between scientific research, pharmaceutical development, intellectual property, and future healthcare applications. The patent publications demonstrate how research concepts can progress toward defined pharmaceutical technologies and create a foundation for further development, regulatory evaluation, strategic partnerships, and potential commercialization.
.
ZeeVieZee BioPharma continues to recognize the strategic importance of intellectual property in pharmaceutical R&D. Through innovation-focused research and development, the company aims to contribute to the advancement of differentiated pharmaceutical solutions while supporting the conversion of scientific concepts into technologies with potential clinical and commercial value.
Patent information referenced in this section is based on publicly available patent records. Patent applications, grants, legal status, claims, and territorial rights may differ between jurisdictions and should be verified through the relevant official patent databases before making regulatory, legal, ownership, or commercialization claims.